Charles Rhyee Maintains Hold Rating, Raises Price Target to $492 Amid Near-Term Strength and 2027 Metabolic Concentration Risks
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Charles Rhyee maintains a Hold rating on Medpace Holdings, raising the price target to $492. He cites strong near-term execution, including improved bookings and oncology growth, as positives. However, he warns of medium-term risks regarding revenue concentration in metabolic programs facing roll-offs by 2027. Despite an upwardly revised DCF-based valuation, the uncertain timing of potential headwinds justifies the balanced Hold recommendation.
Charles Rhyee, an analyst from TD Cowen, maintained the Hold rating on Medpace Holdings. The associated price target was raised to $492.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Charles Rhyee has given his Hold rating due to a combination of factors tied to both solid near‑term execution and emerging medium‑term risks. On the positive side, he highlights improved bookings momentum, better commercial indicators such as higher RFP activity and win rates, and a healthier mix with oncology accounting for roughly half of recent awards, all of which support continued growth into 2026.
At the same time, Rhyee flags rising revenue concentration in a small number of sizable metabolic programs as a key overhang for 2027, since these trials will eventually roll off and management itself sees metabolic exposure stepping down from current levels. Although non‑metabolic revenue is growing and management expects both gross and net bookings to increase sequentially through 2026, the uncertain magnitude and timing of a potential metabolic-related revenue headwind in 2027 tempers his conviction. As a result, even with an upwardly revised price target to $492 based on his DCF work, he believes a balanced risk‑reward profile is best reflected in a Hold rating at this time.
Rhyee covers the Healthcare sector, focusing on stocks such as Cencora, Charles River Labs, and McKesson. According to TipRanks, Rhyee has an average return of 5.5% and a 51.42% success rate on recommended stocks.